ABSTRACT
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst(1,2,3)) and sst(5). Because of this binding profile, pasireotide may offer symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR. This was a phase II, open-label, multicenter study of pasireotide in patients with advanced NET whose symptoms of carcinoid syndrome (diarrhea/flushing) were inadequately controlled by octreotide LAR. Patients received s.c. pasireotide 150??g twice daily (bid), escalated to a maximum dose of 1200??g bid until a clinical response was achieved. Forty-four patients were evaluated for efficacy and 45 for tolerability. Pasireotide 600-900??g s.c. bid effectively controlled the symptoms of diarrhea and flushing in 27% of patients. Evaluation of tumor response in 23 patients showed 13 with stable disease and ten with progressive disease at study end. The most common drug-related adverse events were nausea (27%), abdominal pain (20%), weight loss (20%), and hyperglycemia (16%) and most were of mild or moderate severity. Pasireotide 600-900??g s.c. bid was effective and generally well tolerated in controlling the symptoms of carcinoid syndrome in 27% of patients with advanced NET refractory or resistant to octreotide LAR therapy.
Free Article
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
Riferimento:
Endocr Relat Cancer. 2012 Sep 14;19(5):657-66.
Autori:
Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B.
Fonte:
Endocr Relat Cancer. 2012 Sep 14;19(5):657-66.
Anno:
2012
Azione:
Pasireotide (SOM230), un nuovo multi-recettore analogo della somatostatina (sst), in dosi di 600-900 mg sc è efficace e generalmente ben tollerato nel controllo dei sintomi della sindrome carcinoide nei pazienti con tumori neuroendocrini avanzati (NET) refrattari o resistente alla terapia con octreotide LAR.
Target:
Pasireotide/tumori neuroendocrini avanzati.
Sostanze: